Smarter use of existing treatment helps dramatically boost survival of young AML patients (video 2010)

The default player for embedding or displaying video on stjude.org. Default size: 480x270


More individualized therapy and better supportive care helped push the survival for children with acute myeloid leukemia (AML) to 71 percent three years after diagnosis, according to new research led by St. Jude Children’s Research Hospital investigators and reported in the medical journal The Lancet Oncology. The survival rate of 71 percent is 20 percent better than previously reported U.S. rates and is similar to the success achieved in a 2009 Japanese study. Jeffrey Rubnitz, M.D., Ph.D.,of the St. Jude Oncology department, is the study’s lead author.